Musab Alqasrawi
Interventional Cardiology · Des Moines, IANPI 1235570128
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,886 of the $5,912 with a category attached, or 65.7%. 14 manufacturers reported payments, led by Medtronic at 41.0% of the total. Reporting peaked in 2020 at $3,071 and has fallen 84.7% since, to $471 in 2025.
Across 127 payments — averaging $46.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Edwards Lifesciences$1K
- Abbott$755
- Abiomed$284
- Boston Scientific$272
- Inari Medical, Inc.$255
- plus $491 from 8 others
What the payments were for
- Travel & lodging$1,98434%
- Food & beverage$3,88666%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $2,424 |
| Edwards Lifesciences | 6 | $1,431 |
| Abbott | 50 | $755 |
| Abiomed | 7 | $284 |
| Boston Scientific | 5 | $272 |
| Inari Medical, Inc. | 4 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $170 |
| Cardinal Health 200 LLC | 2 | $92 |
| Cardiovascular Systems Inc. | 2 | $88 |
| Novartis | 2 | $65 |
| Chiesi USA, Inc. | 2 | $30 |
| Shockwave Medical, Inc | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,912 in reported general payments places this provider in the 60th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $170,073 |
| XareltoRivaroxaban | 47 | $43,786 |
| EntrestoSacubitril/Valsartan | 52 | $37,090 |
| BrilintaTicagrelor | 44 | $25,900 |
| JardianceEmpagliflozin | 21 | $14,215 |
| Repatha SureclickEvolocumab | 15 | $9,313 |
| Praluent PenAlirocumab | 12 | $6,599 |
| Metoprolol Succinate | 396 | $3,517 |
| Propafenone Hcl | 22 | $2,316 |
| ClopidogrelClopidogrel Bisulfate | 263 | $1,932 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $1,708 |
| Atorvastatin Calcium | 231 | $1,361 |
| Dilt-XrDiltiazem Hcl | 66 | $1,217 |
| Ezetimibe | 26 | $794 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 34 | $783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $170,073182 claims |
| NovartisEntresto | $65 | $37,09052 claims |
| AstraZenecaBrilinta | $16 | $25,90044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Des Moines
- Atul ChawlaDes Moines$78K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
- Abdulrahman AbdulbakiDes Moines$43K
- Ravinder DerveshDes Moines$3K
- Hamza OglatDes Moines$924
- Aaron FromDes Moines$793
- Martin AronowDes Moines$232
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.